
미국 Accegen은 생명과학 연구와 의약품 개발을 지원하기 위해 다양한 세포주와 생물학적 제품을 제공하는 바이오 제품 제조 기업입니다.

제품 설명
SUIT-2
제품 번호
ABC-TC1175
제품 특징
| Product Code | Suit-2; SUIT 2; SUIT2; Suit2; SUIzo Tumor-2 |
| Species | Human |
| Cat.No | ABC-TC1175 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Pancreas Cancer Cell Lines |
Description
SUIT-2 is a human pancreatic cancer cell line derived from a liver metastasis of moderately differentiated tubular adenocarcinoma in a Japanese male patient. The cells exhibit an epithelial-like morphology with two distinct subpopulations under phase-contrast microscopy: one spindle-shaped and elongated, the other polygonal and epithelial. SUIT-2 cells express several pancreatic ductal markers including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CSPG2/versican, and Mac25/angiomodulin. Electron microscopy confirms features of pancreatic ductal epithelium. Karyotype analysis shows aneuploidy, consistent with malignant transformation. SUIT-2 cells are tumorigenic and metastatic, capable of forming tumors and spreading to regional lymph nodes in nude mouse xenografts.


Citation
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Chen, W.C., To, M.D., Westcott, P.M., Delrosario, R., Kim, I.J., Philips, M., Tran, Q., Bollam, S.R., Goodarzi, H., Bayani, N. and Mirzoeva, O., 2021. Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells. Nature communications, 12(1), pp.1-14.
Application
SUIT-2 is a useful tool to investigate the biological activity of pancreatic ductal adenocarcinoma, identify novel targets or markers for diagnosis, prognosis, and therapy, and contribute to understanding of the interactions between cancer and the host. For example, SUIT-2 can be used to demonstrate how growth factors regulate cell proliferation of tumor cells and the impact of motility-related factors on migration and metastasis.
Frequently Asked Questions
JIMT-1 cell line doubling time is 30-40h, and it is recommended to change medium every 2-3 days.
JIMT-1 cells overexpress HER-2 mRNA and are insensitive to drugs that inhibit HER-2 (such as trastuzumab). JIMT-1 cells have an amplified HER-2 oncogene, which showed no identifiable mutations in its coding sequence.
The cell line lacks expression of hormone receptors (estrogen receptors and progesterone receptors) and is phenotypically of epithelial progenitor cell origin.
The recommended cell density for JIMT-1 cells before passage is 1-2 × 10^5 cells/mL. We recommend to use a T-25 setup at a dilution of 1:5-1:10 (our cell count is approximately 1-2M/vial).
Accegen의 모든 제품들을 만나 보세요!
PRODUCTS
Accegen - Official Distributor in South Korea "Morebio" 한국 공식 대리점 "모아바이오"